Combined bevacizumab and triamcinolone acetonide injections for macular edema in a patient with astrocytic hamartomas and tuberous sclerosis

Ophthalmic Surg Lasers Imaging Retina. 2013 Jan-Feb;44(1):85-90. doi: 10.3928/23258160-20121221-19.


Retinal astrocytic hamartoma or retinal astrocytoma is the best-known ocular manifestation of tuberous sclerosis complex, a neurocutaneous syndrome characterized by the development of multiple disseminated hamartomas. It can have several clinical presentations, ranging from unilateral transparent, noncalcified lesions to bilateral multinodular, mulberry-like calcified tumors. Symptoms appear if the tumor involves the macula and can cause visual loss on the basis of progressive retinal degeneration. The authors report a case of a patient with tuberous sclerosis, bilateral astrocytic hamartomas, and macular edema with intraretinal hemorrhage in the left eye that has responded well to treatment with bevacizumab and intravitreal triamcinolone acetonide.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Drug Therapy, Combination
  • Female
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use*
  • Hamartoma / diagnosis
  • Hamartoma / drug therapy*
  • Humans
  • Intravitreal Injections
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy*
  • Retinal Diseases / diagnosis
  • Retinal Diseases / drug therapy*
  • Tomography, Optical Coherence
  • Triamcinolone Acetonide / therapeutic use*
  • Tuberous Sclerosis / diagnosis
  • Tuberous Sclerosis / drug therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors


  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Triamcinolone Acetonide